跳至主要内容
临床试验/NCT06868446
NCT06868446已完成1 期

Dosage, Feasibility, Acceptability and Usability of OTX-601

Oui Therapeutics, Inc.1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2025年6月30日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
40
试验地点
1
主要终点
PTSD Checklist for DSM-V (PCL-5)

研究概览

简要总结

This study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.

详细描述

The purpose of this study is to conduct a randomized controlled trial to evaluate the usability and feasibility as well as the safety and effectiveness of OTX-601 (version 1) + TAU compared to OTX-601 (version 2) + TAU in reducing PTSD symptoms from baseline to 7 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Posttraumatic stress disorder (PTSD) diagnosis
  • Anxiety Sensitivity Index 3 (ASI-3) scores above 24
  • PTSD Checklist for DSM-V (PCL-5) scores above 30
  • Understands and speaks English
  • Access to a smartphone that is connected to the internet

排除标准

  • Score of 24 or lower on the ASI-3
  • Score of 30 and below on the PCL-5
  • No PTSD diagnosis
  • Active psychosis
  • Acute intoxication during study baseline
  • Enrolled in another treatment research study
  • Medical illness that would prevent the completion of interoceptive exposure exercises

结局指标

主要结局

PTSD Checklist for DSM-V (PCL-5)

时间窗: Baseline, week 1, week 2, week 3, and week 7

Change in PTSD symptoms will be ascertained with the PTSD Checklist for DSM-V (PCL-5). The PCL-5 total score ranges from 0 to 80, with higher scores indicating more severe symptoms.

System Usability Scale (SUS)

时间窗: week 1, week 2, and week 3

App usability will be ascertained with the System Usability Scale (SUS). The SUS provides a score from 0 to 100. An average SUS score equal to or greater than 68 is considered usable.

次要结局

  • Anxiety Sensitivity Index 3 (ASI-3)(Baseline, week 1, week 2, week 3 and week 7)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验